NasdaqGS:NBIXBiotechs
Neurocrine Expands CNS Pipeline With Nxera Schizophrenia Trial And Milestones
Neurocrine Biosciences (NasdaqGS:NBIX) has started a Phase 2 clinical trial in schizophrenia for its candidate NBI-1117570.
The trial, conducted in partnership with Nxera Pharma, has begun dosing the first patient.
This program expands Neurocrine's development efforts beyond its established movement disorder focus.
Neurocrine Biosciences enters this new study with its shares at $131.44 and a 1 year return of 31.3%. Over 3 and 5 years, returns of 25.3% and 35.5% reflect longer term share...